Supernus Pharmaceuticals Inc banner

Wall St Price Targets

SUPN Price Forecast
Based on 6 analysts

+69% Upside
from $28.61 today

Supernus Pharmaceuticals Inc (SUPN)’s 12-month stock price forecast through November 2027 has a consensus target of $48.45, implying 69% upside. The forecast is based on price targets from 6 Wall Street analysts.

SUPN Analyst Rating
Based on 7 analysts

avg. 4.71 of 5
Strong buy
5 71%
Buy
2 29%
Hold
0 0%
Sell
0 0%
Strong sell
0 0%

Analysts rate SUPN Strong buy, with 7 of 7 recommending Buy or Strong buy.

Supernus Pharmaceuticals Inc Competitors:
Price Targets

Financial Estimates

Past growth per year

Average annual growth cannot be calculated for these periods.

Explore analyst estimates, growth and forecast ranges.

Reported Lowest–highest estimate

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is SUPN's stock price target?
Price Target
48.45 USD

According to Wall Street analysts, the average 1-year price target for SUPN is 48.45 USD with a low forecast of 45.45 USD and a high forecast of 55.65 USD.

What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
0%

Over the last 13 years, the compound annual growth rate for Revenue has been 68%. The projected CAGR for the next 8 years is 0%.

What is the Gross Profit forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
0%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 65%. The projected CAGR for the next 8 years is 0%.

What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%

The compound annual growth rate for Operating Income over the next 8 years is 8%.

What is the Pre-Tax Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
56%

The compound annual growth rate for Pre-Tax Income over the next 3 years is 56%.

What is the Net Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
11%

The compound annual growth rate for Net Income over the next 8 years is 11%.

Back to Top